Restatement of Previously Issued Consolidated Financial Statements (Tables)

12 Months Ended

Dec. 31, 2023

Accounting Changes and Error Corrections [Abstract]

Schedule of Corrections of the Misstatements

The impact of the correction of the misstatements is summarized below (in thousands):

	As of December 31, 2022
Corrected Consolidated Balance Sheets	As previously reported		Adjustment		As Restated
Accrued expenses and other liabilities	$	9,900	$	10,071	$	19,971
Total current liabilities	18,460		10,071		28,531
Total liabilities	24,580		10,071		34,651
Accumulated deficit	(213,018)		(10,071)		(223,089)
Total stockholders' equity	84,052		(10,071)		73,981

	For the Fiscal Year Ended December 31, 2022
Corrected Consolidated Statements of Operations and Comprehensive Loss	As previously reported		Adjustment	As Restated
Collaborative arrangement revenue	$	—	2,488	$	2,488
Total revenue	—		2,488	2,488
Research and Development	49,757		6,402	56,159
General and administrative	35,111		289	35,400
Total operating expenses	84,868		6,691	91,559
Loss from operations	(84,868)		(4,203)	(89,071)
Other income (expense), net	3,517		(1,250)	2,267
Net loss	(81,351)		(5,453)	(86,804)
Comprehensive loss	(81,325)		(5,453)	(86,778)
Net loss per share of common stock - basic and diluted	$	(0.38)	(0.02)	$	(0.40)

	For the Fiscal Year Ended December 31, 2022
Corrected Consolidated Statements of Cash Flows	As previously reported		Adjustment		As Restated
Net loss	$	(81,351)	$	(5,453)	$	(86,804)
Non-cash (income) expense from collaborative arrangements, net	—		6,603		6,603
Other	479		(1,150)		(671)
Net cash used in operating activities	(60,079)		—		(60,079)

	Accumulated Deficit						Total Stockholder Equity
Corrected Consolidated Statements of Stockholders' Equity	As previously reported		Adjustment		As Restated		As previously reported		Adjustment		As Restated
Balance at December 31, 2021	$	(131,667)	$	(4,618)	$	(136,285)	$	95,818	$	(4,618)	$	91,200
Stock-based compensation expense	—		—		—		10,541		—		10,541
Issuance of common stock for stock option exercises and restricted stock unit vesting, net	—		—		—		1,262		—		1,262
Issuance of common stock for capital raises, net	—		—		—		57,756		—		57,756
Series A convertible preferred stock conversion	—		—		—		—		—		—
Other comprehensive income (loss)	—		—		—		26		—		26
Net Loss	(81,351)		(5,453)		(86,804)		(81,351)		(5,453)		(86,804)
Balance at December 31, 2022	$	(213,018)	$	(10,071)	$	(223,089)	$	84,052	$	(10,071)	$	73,981

The restated impact of the correction of the misstatements is summarized below (in thousands):

	As of March 31, 2023					As of March 31, 2022
Corrected Condensed Consolidated Balance Sheets (Unaudited)	As previously reported		Adjustment	As Restated		As previously reported		Adjustment	As Restated
Assets
Current assets
Cash and cash equivalents	$	68,259	—	$	68,259	$	129,771	—	$	129,771
Marketable securities	8,462		—	8,462		—		—	—
Prepaid expenses and other current assets	7,680		—	7,680		8,256		—	8,256
Total current assets	84,401		—	84,401		138,027		—	138,027
Property and equipment, net	7,952		—	7,952		1,921		—	1,921
Restricted cash	—		—	—		151		—	151
Other assets	3,946		—	3,946		1,628		—	1,628
Total assets	$	96,299	—	$	96,299	$	141,727	—	$	141,727
Liabilities and stockholders' equity
Current liabilities
Accounts payable	$	8,092	—	$	8,092	$	3,896	—	$	3,896
Accrued expenses and other current liabilities	5,823		10,899	16,722		3,537		5,614	9,151
Operating lease obligations	512		—	512		254		—	254
Current portion of long term debt	1,256		—	1,256		—		—	—
Total current liabilities	15,683		10,899	26,582		7,687		5,614	13,301
Non-current liabilities
Operating lease obligations, less current portion	3,449		—	3,449		1,180		—	1,180
Long term debt, net	1,058		—	1,058		1,731		—	1,731
Other non-current liabilities	309		—	309		—		—	—
Total non-current liabilities	4,816		—	4,816		2,911		—	2,911
Total liabilities	20,499		10,899	31,398		10,598		5,614	16,212
Commitments and contingencies
Stockholders' equity
Convertible preferred stock
Series A	—		—	—		—		—	—
Series B	1		—	1		1		—	1
Common stock	2,265		—	2,265		2,158		—	2,158
Treasury stock	(48)		—	(48)		(48)		—	(48)
Additional paid-in capital	303,073		—	303,073		278,704		—	278,704
Accumulated other comprehensive income	25		—	25		—		—	—
Accumulated deficit	(229,516)		(10,899)	(240,415)		(149,686)		(5,614)	(155,300)
Total stockholders' equity	75,800		(10,899)	64,901		131,129		(5,614)	125,515
Total liabilities and stockholders' equity	$	96,299	—	$	96,299	$	141,727	—	$	141,727

	As of June 30, 2023					As of June 30, 2022
Corrected Condensed Consolidated Balance Sheets (Unaudited)	As previously reported		Adjustment	As Restated		As previously reported		Adjustment	As Restated
Assets
Current assets
Cash and cash equivalents	$	70,578	—	$	70,578	$	115,005	—	$	115,005
Marketable securities	—		—	—		—		—	—
Prepaid expenses and other current assets	2,874		—	2,874		7,564		—	7,564
Total current assets	73,452		—	73,452		122,569		—	122,569
Property and equipment, net	11,720		—	11,720		3,153		—	3,153
Other assets	3,804		—	3,804		4,366		—	4,366
Total assets	$	88,976	—	$	88,976	$	130,088	—	$	130,088
Liabilities and stockholders' equity
Current liabilities
Accounts payable	$	3,881	—	$	3,881	$	5,921	—	$	5,921
Accrued expenses and other current liabilities	7,787		11,039	18,826		4,103		7,625	11,728
Operating lease obligations	526		—	526		314		—	314
Current portion of long term debt	1,266		—	1,266		—		—	—
Total current liabilities	13,460		11,039	24,499		10,338		7,625	17,963
Non-current liabilities
Operating lease obligations, less current portion	3,308		—	3,308		3,892		—	3,892
Long term debt, net	1,472		—	1,472		1,750		—	1,750
Other non-current liabilities	455		—	455		—		—	—
Total non-current liabilities	5,235		—	5,235		5,642		—	5,642
Total liabilities	18,695		11,039	29,734		15,980		7,625	23,605
Commitments and contingencies
Stockholders' equity
Convertible preferred stock
Series A	—		—	—		—		—	—
Series B	1		—	1		1		—	1
Common stock	2,566		—	2,566		2,163		—	2,163
Treasury stock	(48)		—	(48)		(48)		—	(48)
Additional paid-in capital	320,181		—	320,181		281,139		—	281,139
Accumulated other comprehensive income	22		—	22		10		—	10
Accumulated deficit	(252,441)		(11,039)	(263,480)		(169,157)		(7,625)	(176,782)
Total stockholders' equity	70,281		(11,039)	59,242		114,108		(7,625)	106,483
Total liabilities and stockholders' equity	$	88,976	—	$	88,976	$	130,088	—	$	130,088

	As of September 30, 2023					As of September 30, 2022
Corrected Condensed Consolidated Balance Sheets (Unaudited)	As previously reported		Adjustment	As Restated		As previously reported		Adjustment	As Restated
Assets
Current assets
Cash and cash equivalents	$	53,477	—	$	53,477	$	101,602	—	$	101,602
Marketable securities	—		—	—		—		—	—
Prepaid expenses and other current assets	3,081		—	3,081		5,895		—	5,895
Total current assets	56,558		—	56,558		107,497		—	107,497
Property and equipment, net	14,469		—	14,469		4,517		—	4,517
Other assets	3,660		—	3,660		4,225		—	4,225
Total assets	$	74,687	—	$	74,687	$	116,239	—	$	116,239
Liabilities and stockholders' equity
Current liabilities
Accounts payable	$	2,921	—	$	2,921	$	6,460	—	$	6,460
Accrued expenses and other current liabilities	6,399		8,594	14,993		8,004		9,616	17,620
Operating lease obligations	540		—	540		443		—	443
Current portion of long term debt	1,276		—	1,276		—		—	—
Total current liabilities	11,136		8,594	19,730		14,907		9,616	24,523
Non-current liabilities
Operating lease obligations, less current portion	3,164		—	3,164		3,764		—	3,764
Long term debt, net	1,495		—	1,495		2,265		—	2,265
Other non-current liabilities	497		—	497		—		—	—
Total non-current liabilities	5,156		—	5,156		6,029		—	6,029
Total liabilities	16,292		8,594	24,886		20,936		9,616	30,552
Commitments and contingencies
Stockholders' equity
Convertible preferred stock
Series A	—		—	—		—		—	—
Series B	1		—	1		1		—	1
Common stock	2,566		—	2,566		2,168		—	2,168
Treasury stock	(48)		—	(48)		(48)		—	(48)
Additional paid-in capital	322,452		—	322,452		284,231		—	284,231
Accumulated other comprehensive income	27		—	27		30		—	30
Accumulated deficit	(266,603)		(8,594)	(275,197)		(191,079)		(9,616)	(200,695)
Total stockholders' equity	58,395		(8,594)	49,801		95,303		(9,616)	85,687
Total liabilities and stockholders' equity	$	74,687	—	$	74,687	$	116,239	—	$	116,239

	For the Three Months Ended
	March 31, 2023					March 31, 2022
Corrected Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	As previously reported		Adjustment	As Restated		As previously reported		Adjustment	As Restated
Collaborative arrangement revenue	$	—	443	$	443	$	—	500	$	500
Total revenue	—		443	443		—		500	500
Operating expenses
Research and development	9,558		614	10,172		7,915		1,478	9,393
General and administrative	8,193		113	8,306		10,119		18	10,137
Total operating expenses	17,751		727	18,478		18,034		1,496	19,530
Loss from operations	(17,751)		(284)	(18,035)		(18,034)		(996)	(19,030)
Other income (expense), net	1,253		(544)	709		15		—	15
Net loss	$	(16,498)	(828)	$	(17,326)	$	(18,019)	(996)	$	(19,015)
Other comprehensive income (loss)
Foreign currency translation adjustment	(1)		—	(1)		—		—	—
Comprehensive loss	$	(16,499)	(828)	$	(17,327)	$	(18,019)	(996)	$	(19,015)
Shares used in calculating net loss per common share — basic and diluted	225,523,627		—	225,523,627		205,693,498		—	205,693,498
Net loss per share of common stock — basic and diluted	$	(0.07)	(0.01)	$	(0.08)	$	(0.09)	—	$	(0.09)

	For the Three Months Ended
	June 30, 2023					June 30, 2022
Corrected Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	As previously reported		Adjustment	As Restated		As previously reported		Adjustment	As Restated
Collaborative arrangement revenue	$	—	485	$	485	$	—	643	$	643
Total revenue	—		485	485		—		643	643
Operating expenses
Research and development	14,169		405	14,574		9,007		2,595	11,602
General and administrative	9,564		(113)	9,451		10,558		59	10,617
Total operating expenses	23,733		292	24,025		19,565		2,654	22,219
Loss from operations	(23,733)		193	(23,540)		(19,565)		(2,011)	(21,576)
Other income (expense), net	808		(333)	475		94		—	94
Net loss	$	(22,925)	(140)	$	(23,065)	$	(19,471)	(2,011)	$	(21,482)
Other comprehensive income (loss)
Foreign currency translation adjustment	(2)		—	(2)		10		—	10
Unrealized gain (loss) on marketable securities	(1)		—	(1)		—		—	—
Comprehensive loss	$	(22,928)	(140)	$	(23,068)	$	(19,461)	(2,011)	$	(21,472)
Shares used in calculating net loss per common share — basic and diluted	238,311,498		—	238,311,498		215,862,977		—	215,862,977
Net loss per share of common stock — basic and diluted	$	(0.10)	—	$	(0.10)	$	(0.09)	(0.01)	$	(0.10)

	For the Six Months Ended
	June 30, 2023					June 30, 2022
Corrected Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	As previously reported		Adjustment	As Restated		As previously reported		Adjustment	As Restated
Collaborative arrangement revenue	$	—	928	$	928	$	—	1,143	$	1,143
Total revenue	—		928	928		—		1,143	1,143
Operating expenses
Research and development	23,727		1,019	24,746		16,922		4,073	20,995
General and administrative	17,757		—	17,757		20,677		77	20,754
Total operating expenses	41,484		1,019	42,503		37,599		4,150	41,749
Loss from operations	(41,484)		(91)	(41,575)		(37,599)		(3,007)	(40,606)
Other income (expense), net	2,061		(877)	1,184		109		—	109
Net loss	$	(39,423)	(968)	$	(40,391)	$	(37,490)	(3,007)	$	(40,497)
Other comprehensive income (loss)
Foreign currency translation adjustment	(3)		—	(3)		10		—	10
Unrealized gain (loss) on marketable securities	(1)		—	(1)		—		—	—
Comprehensive loss	$	(39,427)	(968)	$	(40,395)	$	(37,480)	(3,007)	$	(40,487)
Shares used in calculating net loss per common share — basic and diluted	231,952,888		—	231,952,888		210,806,330		—	210,806,330
Net loss per share of common stock — basic and diluted	$	(0.17)	—	$	(0.17)	$	(0.18)	(0.01)	$	(0.19)

	For the Three Months Ended
	September 30, 2023					September 30, 2022
Corrected Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	As previously reported		Adjustment	As Restated		As previously reported		Adjustment	As Restated
Collaborative arrangement revenue	$	—	3,699	$	3,699	$	—	466	$	466
Total revenue	—		3,699	3,699		—		466	466
Operating expenses
Research and development	6,342		706	7,048		15,622		2,315	17,937
General and administrative	9,082		—	9,082		7,497		142	7,639
Total operating expenses	15,424		706	16,130		23,119		2,457	25,576
Loss from operations	(15,424)		2,993	(12,431)		(23,119)		(1,991)	(25,110)
Other income (expense), net	1,262		(548)	714		1,197		—	1,197
Net loss	$	(14,162)	2,445	$	(11,717)	$	(21,922)	(1,991)	$	(23,913)
Other comprehensive income (loss)
Foreign currency translation adjustment	5		—	5		20		—	20
Unrealized gain (loss) on marketable securities	—		—	—		—		—	—
Comprehensive loss	$	(14,157)	2,445	$	(11,712)	$	(21,902)	(1,991)	$	(23,893)
Shares used in calculating net loss per common share — basic and diluted	256,492,558		—	256,492,558		216,591,011		—	216,591,011
Net loss per share of common stock — basic and diluted	$	(0.06)	0.01	$	(0.05)	$	(0.10)	(0.01)	$	(0.11)

	For the Nine Months Ended
	September 30, 2023					September 30, 2022
Corrected Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	As previously reported		Adjustment	As Restated		As previously reported		Adjustment	As Restated
Collaborative arrangement revenue	$	—	4,627	$	4,627	$	—	1,609	$	1,609
Total revenue	—		4,627	4,627		—		1,609	1,609
Operating expenses
Research and development	30,069		1,725	31,794		32,544		6,388	38,932
General and administrative	26,839		—	26,839		28,174		219	28,393
Total operating expenses	56,908		1,725	58,633		60,718		6,607	67,325
Loss from operations	(56,908)		2,902	(54,006)		(60,718)		(4,998)	(65,716)
Other income (expense), net	3,323		(1,425)	1,898		1,306		—	1,306
Net loss	$	(53,585)	1,477	$	(52,108)	$	(59,412)	(4,998)	$	(64,410)
Other comprehensive income (loss)
Foreign currency translation adjustment	2		—	2		30		—	30
Unrealized gain (loss) on marketable securities	(1)		—	(1)		—		—	—
Comprehensive loss	$	(53,584)	1,477	$	(52,107)	$	(59,382)	(4,998)	$	(64,380)
Shares used in calculating net loss per common share — basic and diluted	240,222,667		—	240,222,667		212,755,746		—	212,755,746
Net loss per share of common stock — basic and diluted	$	(0.22)	—	$	(0.22)	$	(0.28)	(0.02)	$	(0.30)

	For the Nine Months Ended September 30, 2022
	Series A Convertible Preferred Stock			Series B Convertible Preferred Stock			Common Stock			Treasury Stock		Additional Paid in Capital		Accumulated Other Comprehensive Income		Accumulated Deficit		Total
Corrected Condensed Consolidated Statements of Stockholders' equity (Unaudited)	Shares	Amount		Shares	Amount		Shares	Amount
Balance December 31, 2021 (As Reported)	7	$	—	54,745	$	1	199,502,183	$	1,995	$	(48)	$	225,537	$	—	$	(131,667)	$	95,818
Stock-based compensation expense	—	—		—	—		—	—		—		3,299		—		—		3,299
Issuance of common stock for stock option exercises and restricted stock unit vesting, net	—	—		—	—		277,323	3		—		177		—		—		180
Issuance of common stock for capital raises, net	—	—		—	—		15,973,420	160		—		49,691		—		—		49,851
Net loss	—	—		—	—		—	—		—		—		—		(18,019)		(18,019)
Balance March 31, 2022 (As Reported)	7	$	—	54,745	$	1	215,752,926	$	2,158	$	(48)	$	278,704	$	—	$	(149,686)	$	131,129
Stock-based compensation expense	—	—		—	—		—	—		—		2,079		—		—		2,079
Issuance of common stock for stock option exercises and restricted stock unit vesting, net	—	—		—	—		515,221	5		—		356		—		—		361
Series A convertible preferred stock conversion	(7)	—		—	—		3,115	—		—		—		—		—		—
Other Comprehensive income (loss)	—	—		—	—		—	—		—		—		10		—		10
Net loss	—	—		—	—		—	—		—		—		—		(19,471)		(19,471)
Balance June 30, 2022 (As Reported)	—	$	—	54,745	$	1	216,271,262	$	2,163	$	(48)	$	281,139	$	10	$	(169,157)	$	114,108
Stock-based compensation expense	—	—		—	—		—	—		—		2,495		—		—		2,495
Issuance of common stock for stock option exercises and restricted stock unit vesting, net	—	—		—	—		538,675	5		—		597		—		—		602
Other Comprehensive income (loss)	—	—		—	—		—	—		—		—		20		—		20
Net loss	—	—		—	—		—	—		—		—		—		(21,922)		(21,922)
Balance September 30, 2022 (As Reported)	—	$	—	54,745	$	1	216,809,937	$	2,168	$	(48)	$	284,231	$	30	$	(191,079)	$	95,303

	For the Nine Months Ended September 30, 2022
	Series A Convertible Preferred Stock		Series B Convertible Preferred Stock		Common Stock		Treasury Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit		Total
Condensed Consolidated Statements of Stockholders' equity (Unaudited) Adjustments	Shares	Amount	Shares	Amount	Shares	Amount
Balance December 31, 2021	—	—	—	—	—	—	—	—	—	$	(4,618)	$	(4,618)
Net loss	—	—	—	—	—	—	—	—	—	(996)		(996)
Balance March 31, 2022 (Adjustment)	—	—	—	—	—	—	—	—	—	$	(5,614)	$	(5,614)
Net loss	—	—	—	—	—	—	—	—	—	(2,011)		(2,011)
Balance June 30, 2022 (Adjustment)	—	—	—	—	—	—	—	—	—	$	(7,625)	$	(7,625)
Net loss	—	—	—	—	—	—	—	—	—	(1,991)		(1,991)
Balance at September 30, 2022 (Adjustment)	—	—	—	—	—	—	—	—	—	$	(9,616)	$	(9,616)

	For the Nine Months Ended September 30, 2022
	Series A Convertible Preferred Stock			Series B  Convertible Preferred Stock			Common Stock			Treasury Stock		Additional Paid in Capital		Accumulated Other Comprehensive Income		Accumulated Deficit		Total
Corrected Condensed Consolidated Statements of Stockholders' equity (Unaudited)	Shares	Amount		Shares	Amount		Shares	Amount
Balance December 31, 2021 (As Restated)	7	$	—	54,745	$	1	199,502,183	$	1,995	$	(48)	$	225,537	$	—	$	(136,285)	$	91,200
Stock-based compensation expense	—	—		—	—		—	—		—		3,299		—		—		3,299
Issuance of common stock for stock option exercises and restricted stock unit vesting, net	—	—		—	—		277,323	3		—		177		—		—		180
Issuance of common stock for capital raises, net	—	—		—	—		15,973,420	160		—		49,691		—		—		49,851
Net loss	—	—		—	—		—	—		—		—		—		(19,015)		(19,015)
Balance March 31, 2022 (As Restated)	7	$	—	54,745	$	1	215,752,926	$	2,158	$	(48)	$	278,704	$	—	$	(155,300)	$	125,515
Stock-based compensation expense	—	—		—	—		—	—		—		2,079		—		—		2,079
Issuance of common stock for stock option exercises and restricted stock unit vesting, net	—	—		—	—		515,221	5		—		356		—		—		361
Series A convertible preferred stock conversion	(7)	—		—	—		3,115	—		—		—		—		—		—
Other Comprehensive income (loss)	—	—		—	—		—	—		—		—		10		—		10
Net loss	—	—		—	—		—	—		—		—		—		(21,482)		(21,482)
Balance June 30, 2022 (As Restated)	—	—		54,745	1		216,271,262	2,163		(48)		281,139		10		(176,782)		106,483
Stock-based compensation expense	—	—		—	—		—	—		—		2,495		—		—		2,495
Issuance of common stock for stock option exercises and restricted stock unit vesting, net	—	—		—	—		538,675	5		—		597		—		—		602
Other Comprehensive income (loss)	—	—		—	—		—	—		—		—		20		—		20
Net loss	—	—		—	—		—	—		—		—		—		(23,913)		(23,913)
Balance September 30, 2022 (As Restated)	—	$	—	54,745	$	1	216,809,937	$	2,168	$	(48)	$	284,231	$	30	$	(200,695)	$	85,687

	For the Nine Months Ended September 30, 2023
	Series A Convertible Preferred Stock			Series B Convertible Preferred Stock			Common Stock			Treasury Stock		Additional Paid in Capital		Accumulated Other Comprehensive Income		Accumulated Deficit		Total
Corrected Condensed Consolidated Statements of Stockholders' equity (Unaudited)	Shares	Amount		Shares	Amount		Shares	Amount
Balance December 31, 2022 (As Reported)	—	$	—	54,745	$	1	221,721,182	$	2,217	$	(48)	$	294,874	$	26	$	(213,018)	$	84,052
Stock-based compensation expense	—	—		—	—		—	—		—		2,689		—		—		2,689
Issuance of common stock for stock option exercises and restricted stock unit vesting, net	—	—		—	—		348,555	3		—		(4)		—		—		(1)
Issuance of common stock for capital raises, net	—	—		—	—		4,478,956	45		—		5,514		—		—		5,559
Other comprehensive income (loss)	—	—		—	—		—	—		—		—		(1)		—		(1)
Net loss	—	—		—	—		—	—		—		—		—		(16,498)		(16,498)
Balance March 31, 2023 (As Reported)	—	$	—	54,745	$	1	226,548,693	$	2,265	$	(48)	$	303,073	$	25	$	(229,516)	$	75,800
Stock-based compensation expense	—	—		—	—		—	—		—		2,632		—		—		2,632
Issuance of common stock for stock option exercises and restricted stock unit vesting, net	—	—		—	—		59,859	1		—		9		—		—		10
Issuance of common stock for capital raises, net	—	—		—	—		30,000,000	300		—		14,467		—		—		14,767
Other comprehensive income (loss)	—	—		—	—		—	—		—		—		(3)		—		(3)
Net loss	—	—		—	—		—	—		—		—		—		(22,925)		(22,925)
Balance June 30, 2023 (As Reported)	—	$	—	54,745	$	1	256,608,552	$	2,566	$	(48)	$	320,181	$	22	$	(252,441)	$	70,281
Stock-based compensation expense	—	—		—	—		—	—		—		2,174		—		—		2,174
Issuance of common stock for stock option exercises and restricted stock unit vesting, net	—	—		—	—		12,935	—		—		97		—		—		97
Other comprehensive income (loss)	—	—		—	—		—	—		—		—		5		—		5
Net loss	—	—		—	—		—	—		—		—		—		(14,162)		(14,162)
Balance September 30, 2023 (As Reported)	—	$	—	54,745	$	1	256,621,487	$	2,566	$	(48)	$	322,452	$	27	$	(266,603)	$	58,395

	For the Nine Months Ended September 30, 2023
	Series A Convertible Preferred Stock		Series B Convertible Preferred Stock		Common Stock		Treasury Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit		Total
Condensed Consolidated Statements of Stockholders' equity (Unaudited) Adjustments	Shares	Amount	Shares	Amount	Shares	Amount
Balance December 31, 2022 (Adjustment)	—	—	—	—	—	—	—	—	—	$	(10,071)	$	(10,071)
Net loss	—	—	—	—	—	—	—	—	—	(828)		(828)
Balance March 31, 2023 (Adjustment)	—	—	—	—	—	—	—	—	—	$	(10,899)	$	(10,899)
Net loss	—	—	—	—	—	—	—	—	—	(140)		(140)
Balance June 30, 2023 (Adjustment)	—	—	—	—	—	—	—	—	—	$	(11,039)	$	(11,039)
Net loss	—	—	—	—	—	—	—	—	—	2,445		2,445
Balance at September 30, 2023 (Adjustment)	—	—	—	—	—	—	—	—	—	$	(8,594)	$	(8,594)

	For the Nine Months Ended September 30, 2023
	Series A Convertible Preferred Stock			Series B  Convertible Preferred Stock			Common Stock			Treasury Stock		Additional Paid in Capital		Accumulated Other Comprehensive Income		Accumulated Deficit		Total
Corrected Condensed Consolidated Statements of Stockholders' equity (Unaudited)	Shares	Amount		Shares	Amount		Shares	Amount
Balance December 31, 2022 (As Restated)	—	$	—	54,745	$	1	221,721,182	$	2,217	$	(48)	$	294,874	$	26	$	(223,089)	$	73,981
Stock-based compensation expense	—	—		—	—		—	—		—		2,689		—		—		2,689
Issuance of common stock for stock option exercises and restricted stock unit vesting, net	—	—		—	—		348,555	3		—		(4)		—		—		(1)
Issuance of common stock for capital raises, net	—	—		—	—		4,478,956	45		—		5,514		—		—		5,559
Other comprehensive income (loss)	—	—		—	—		—	—		—		—		(1)		—		(1)
Net loss	—	—		—	—		—	—		—		—		—		(17,326)		(17,326)
Balance March 31, 2023 (As Restated)	—	$	—	54,745	$	1	226,548,693	$	2,265	$	(48)	$	303,073	$	25	$	(240,415)	$	64,901
Stock-based compensation expense	—	—		—	—		—	—		—		2,632		—		—		2,632
Issuance of common stock for stock option exercises and restricted stock unit vesting, net	—	—		—	—		59,859	1		—		9		—		—		10
Issuance of common stock for capital raises, net	—	—		—	—		30,000,000	300		—		14,467		—		—		14,767
Other comprehensive income (loss)	—	—		—	—		—	—		—		—		(3)		—		(3)
Net loss	—	—		—	—		—	—		—		—		—		(23,065)		(23,065)
Balance June 30, 2023 (As Restated)	—	$	—	54,745	$	1	256,608,552	$	2,566	$	(48)	$	320,181	$	22	$	(263,480)	$	59,242
Stock-based compensation expense	—	—		—	—		—	—		—		2,174		—		—		2,174
Issuance of common stock for stock option exercises and restricted stock unit vesting, net	—	—		—	—		12,935	—		—		97		—		—		97
Other comprehensive income (loss)	—	—		—	—		—	—		—		—		5		—		5
Net loss	—	—		—	—		—	—		—		—		—		(11,717)		(11,717)
Balance September 30, 2023 (As Restated)	—	$	—	54,745	$	1	256,621,487	$	2,566	$	(48)	$	322,452	$	27	$	(275,197)	$	49,801

	Three months ended March 31,
	2023					2022
Corrected Consolidated Statements of Cash Flows (Unaudited)	As previously reported		Adjustment	As Restated		As previously reported		Adjustment	As Restated
Cash flows from operating activities
Net loss	$	(16,498)	(828)	$	(17,326)	$	(18,019)	(996)	$	(19,015)
Adjustments to reconcile net loss to net cash used in operating activities:			—	—				—	—
Depreciation and amortization expense	174		—	174		76		—	76
Amortization (accretion) on marketable securities	(143)		—	(143)		—		—	—
Non-cash interest expense	24		—	24		19		—	19
Non-cash lease expense	131		—	131		179		—	179
Non-cash (income) expense from collaborative arrangements, net	—		1,008	1,008		—		996	996
Stock-based compensation expense	2,689		—	2,689		3,299		—	3,299
Other	352		—	352		—		—	—
Changes in assets and liabilities:
Prepaid expenses and other current assets	(60)		—	(60)		(575)		—	(575)
Accounts payable and accrued expenses	(4,784)		(180)	(4,964)		131		—	131
Lease obligations	(125)		—	(125)		(176)		—	(176)
Net cash used in operating activities	(18,240)		—	(18,240)		(15,066)		—	(15,066)
Cash flows from investing activities
Purchases of marketable securities	(3,947)		—	(3,947)		—		—	—
Proceeds from maturities of marketable securities	9,000		—	9,000		—		—	—
Purchases of property and equipment	(1,612)		—	(1,612)		(223)		—	(223)
Net cash provided by (used in) investing activities	3,441		—	3,441		(223)		—	(223)
Cash flows from financing activities
Proceeds from issuance of common stock, net	5,731		—	5,731		50,177		—	50,177
Payment of equity issuance costs	(173)		—	(173)		(75)		—	(75)
Payments of debt issuance costs	(62)		—	(62)		—		—	—
Net cash provided by financing activities	5,496		—	5,496		50,102		—	50,102
Effect of changes in exchange rate on cash and cash equivalents	(1)		—	(1)		—		—	—
Net (decrease) in cash, cash equivalents, and restricted cash	(9,304)		—	(9,304)		34,813		—	34,813
Cash, cash equivalents, and restricted cash at beginning of period	77,563		—	77,563		95,109		—	95,109
Cash, cash equivalents, and restricted cash at end of period	$	68,259	—	$	68,259	$	129,922	—	$	129,922
Supplemental disclosure of non-cash investing and financing transactions:
Purchase of property and equipment	$	1,119	—	$	1,119	$	611	—	$	611
Equity issuance costs	$	—	—	$	—	$	71	—	$	71

	Six months ended June 30,
	2023					2022
Corrected Consolidated Statements of Cash Flows (Unaudited)	As previously reported		Adjustment	As Restated		As previously reported		Adjustment	As Restated
Cash flows from operating activities
Net loss	$	(39,423)	(968)	$	(40,391)	$	(37,490)	(3,007)	$	(40,497)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	348		—	348		166		—	166
Amortization (accretion) on marketable securities	(182)		—	(182)		—		—	—
Non-cash interest expense	54		—	54		38		—	38
Non-cash lease expense	265		—	265		334		—	334
Non-cash (income) expense from collaborative arrangements, net	—		1,392	1,392		—		3,007	3,007
Stock-based compensation expense	5,321		—	5,321		5,378		—	5,378
Impairment of advance for COVAXIN supply	4,074		—	4,074		—		—	—
Loss on disposal of fixed assets related to COVAXIN	363		—	363		—		—	—
Other	439		—	439		—		—	—
Changes in assets and liabilities:
Prepaid expenses and other current assets	572		—	572		132		—	132
Accounts payable and accrued expenses	(8,625)		(424)	(9,049)		2,844		—	2,844
Lease obligations	(252)		—	(252)		(265)		—	(265)
Net cash used in operating activities	(37,046)		—	(37,046)		(28,863)		—	(28,863)
Cash flows from investing activities
Purchases of marketable securities	(3,947)		—	(3,947)		—		—	—
Proceeds from maturities of marketable securities	17,500		—	17,500		—		—	—
Purchases of property and equipment	(4,389)		—	(4,389)		(1,589)		—	(1,589)
Net cash provided by (used in) investing activities	9,164		—	9,164		(1,589)		—	(1,589)
Cash flows from financing activities
Proceeds from issuance of common stock, net	20,690		—	20,690		50,538		—	50,538
Payment of equity issuance costs	(222)		—	(222)		(200)		—	(200)
Proceeds from issuance of debt	500		—	500		—		—	—
Payments of debt issuance costs	(68)		—	(68)		—		—	—
Net cash provided by financing activities	20,900		—	20,900		50,338		—	50,338
Effect of changes in exchange rate on cash and cash equivalents	(3)		—	(3)		10		—	10
Net (decrease) in cash and cash equivalents	(6,985)		—	(6,985)		19,896		—	19,896
Cash, cash equivalents, and restricted cash at beginning of period	77,563		—	77,563		95,109		—	95,109
Cash and cash equivalents at end of period	$	70,578	—	$	70,578	$	115,005	—	$	115,005

Corrected Consolidated Statements of Cash Flows (Unaudited) - Continued
Supplemental disclosure of non-cash investing and financing transactions:
Equity issuance costs	$	133	—	$	133	$	69	—	$	69
Purchase of property and equipment	$	2,637	—	$	2,637	$	491	—	$	491
Right-of-use assets related to operating leases	$	—	—	$	—	$	2,918	—	$	2,918

	Nine months ended September 30,
	2023					2022
Corrected Consolidated Statements of Cash Flows (Unaudited)	As previously reported		Adjustment	As Restated		As previously reported		Adjustment	As Restated
Cash flows from operating activities
Net loss	$	(53,585)	1,477	$	(52,108)	$	(59,412)	(4,998)	$	(64,410)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	525		—	525		307		—	307
Amortization (accretion) on marketable securities	(182)		—	(182)		—		—	—
Non-cash interest expense	87		—	87		58		—	58
Non-cash lease expense	401		—	401		463		—	463
Non-cash (income) expense from collaborative arrangements, net	—		(1,134)	(1,134)		—		4,856	4,856
Stock-based compensation expense	7,495		—	7,495		7,873		—	7,873
Impairment of advance for COVAXIN supply	4,074		—	4,074		—		—	—
Loss on disposal of fixed assets related to COVAXIN	363		—	363		—		—	—
Other	379		—	379		(673)		—	(673)
Changes in assets and liabilities:
Prepaid expenses and other current assets	132		—	132		1,888		—	1,888
Accounts payable and accrued expenses	(10,059)		(343)	(10,402)		6,592		142	6,734
Lease obligations	(382)		—	(382)		(261)		—	(261)
Net cash used in operating activities	(50,752)		—	(50,752)		(43,165)		—	(43,165)
Cash flows from investing activities
Purchases of marketable securities	(3,947)		—	(3,947)		—		—	—
Proceeds from maturities of marketable securities	17,500		—	17,500		—		—	—
Purchases of property and equipment	(7,754)		—	(7,754)		(2,433)		—	(2,433)
Repayment of note receivable	—		—	—		761		—	761
Net cash provided by (used in) investing activities	5,799		—	5,799		(1,672)		—	(1,672)
Cash flows from financing activities
Proceeds from issuance of common stock	20,788		—	20,788		51,141		—	51,141
Payment of equity issuance costs	(355)		—	(355)		(298)		—	(298)
Proceeds from issuance of debt	500		—	500		500		—	500
Payments of debt issuance costs	(68)		—	(68)		(43)		—	(43)
Net cash provided by financing activities	20,865		—	20,865		51,300		—	51,300
Effect of changes in exchange rate on cash and cash equivalents	2		—	2		30		—	30
Net (decrease) in cash and cash equivalents	(24,086)		—	(24,086)		6,493		—	6,493
Cash, cash equivalents, and restricted cash at beginning of period	77,563		—	77,563		95,109		—	95,109
Cash and cash equivalents at end of period	$	53,477	—	$	53,477	$	101,602	—	$	101,602

Corrected Consolidated Statements of Cash Flows (Unaudited) - Continued
Supplemental disclosure of non-cash investing and financing transactions:
Equity issuance costs	$	—	—	$	—	$	2	—	$	2
Purchase of property and equipment	$	1,969	—	$	1,969	$	1,231	—	$	1,231
Right-of-use assets related to operating leases	$	—	—	$	—	$	2,916	—	$	2,916
Debt issuance costs	$	—	—	$	—	$	19	—	$	19